Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Arthroscopic injection of a bioadhesive hydrogel implant (JointRep), in conjunction with microfracture, for treatment of osteochondral defects of the knee
2020	National Institute for Health and Care Excellence (NICE)	Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 643
2020	National Institute for Health and Care Excellence (NICE)	Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test). NICE diagnostics guidance 39
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020	National Institute for Health and Care Excellence (NICE)	Entrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 644
2020	NIHR Health Services and Delivery Research programme	Identifying nurse-staffing requirements using the Safer Nursing Care Tool. Modelling the costs and consequences of real world application to address variation in patient need on hospital wards
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Atectura® Breezhaler® (indacaterol acetate/mometasone furoate)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020	National Institute for Health and Care Excellence (NICE)	Avelumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 645
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice reassessment osimertinib (Tagrisso®)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2020	National Institute for Health and Care Excellence (NICE)	Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 646
2020	NIHR Health Technology Assessment programme	Seasonal Influenza Vaccination Effectiveness II (SIVE II): use of a large national primary care and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness
2020	NIHR Public Health Research (PHR) programme	Feasibility study of how best to engage obese men in narrative SMS (short message system) and incentive interventions for weight loss, to inform a future effectiveness and cost-effectiveness trial
2020	NIHR Health Technology Assessment programme	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Avelumab in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Dravet-Syndrome, ≥ 2 years, combination with clobazam)]
2020	National Institute for Health and Care Excellence (NICE)	Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal). NICE technology appraisal guidance 647
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Lennox-Gastaut-Syndrome, ≥ 2 years, combination with clobazam)]
2020	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 648
2020	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 649
2020	NIHR Public Health Research (PHR) programme	Healthy Dads, Healthy Kids UK: a cultural adaptation and feasibility study of a weight management programme for fathers of younger children
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease
2020	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 650
2020	NIHR Health Services and Delivery Research programme	An evaluation of alcohol treatment centres: implications for service delivery, patient benefit and harm reduction
2020	Swiss Federal Office of Public Health (FOPH)	Glinides and glitazones in the treatment of type 2 diabetes
2020	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness and safety of the macrobiotic diet]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020	National Institute for Health and Care Excellence (NICE)	Naldemedine for treating opioid-induced constipation. NICE technology appraisal guidance 651
2020	NIHR Health Technology Assessment programme	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over
2020	National Institute for Health and Care Excellence (NICE)	Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 653
2020	NIHR Health Technology Assessment programme	Examining the benefit of graduated compression stockings as an adjunct to low dose low molecular weight heparin in the prevention of venous thromboembolism in elective surgical inpatients identified as moderate or high risk for venous thromboembolism a multi-centre randomised controlled trial
2020	National Institute for Health and Care Excellence (NICE)	Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 654
2020	NIHR Health Services and Delivery Research programme	Understanding how frontline staff use patient experience data for service improvement - an exploratory case study evaluation and national survey (US-PEx)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sleep position therapy for obstructive sleep apnoea]
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Amnion membrane for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020	National Institute for Health and Care Excellence (NICE)	Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 655
2020	NIHR Health Services and Delivery Research programme	Young people with Attention Deficit Hyperactivity Disorder (ADHD) in transition from children's services to adult services (Catch-uS): a mixed methods project using national surveillance, qualitative and mapping studies
2020	Norwegian Institute of Public Health (NIPH)	[Hyperbaric oxygen therapy for radiation-induced cystitis]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of oral semaglutide (Rybelsus®)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Gilteritinib (Relapsed or Refractory Acute Myeloid Leukaemia with an FLT3 Mutation)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sleep position therapy for obstructive sleep apnoea - Addendum to commission E20-07]
2020	National Institute for Health and Care Excellence (NICE)	Siponimod for treating secondary progressive multiple sclerosis. NICE technology appraisal guidance 656
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2020	National Institute for Health and Care Excellence (NICE)	Carfilzomib for previously treated multiple myeloma. NICE technology appraisal guidance 657
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group
2020	National Institute for Health and Care Excellence (NICE)	Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 658
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum (package advice)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020	National Institute for Health and Care Excellence (NICE)	Galcanezumab for preventing migraine. NICE technology appraisal guidance 659
2020	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Pharmacological treatment of common pain conditions in older persons]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trientine tetrahydrochloride (Cuprior®) [for] the treatment of Wilson's disease
2020	National Institute for Health and Care Excellence (NICE)	Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 660
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of hydroquinine (Inhibin®) for patients with nocturnal muscle cramps
2020	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. NICE technology appraisal guidance 661
2020	European Network for Health Technology Assessment (EUnetHTA)	Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations (package advice)
2020	National Institute for Health and Care Excellence (NICE)	Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 662
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Bevespi® aerosphere 7.2 micrograms / 5 micrograms
2020	National Institute for Health and Care Excellence (NICE)	Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 663
2020	European Network for Health Technology Assessment (EUnetHTA)	Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	3D printing applications in healthcare
2020	National Institute for Health and Care Excellence (NICE)	Liraglutide for managing overweight and obesity. NICE technology appraisal guidance 664
2020	NIHR Health Services and Delivery Research programme	Patient Experience And Reflective Learning (PEARL)
2020	European Network for Health Technology Assessment (EUnetHTA)	Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Technologies for the diagnosis of prostate cancer
2020	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating severe rheumatoid arthritis. NICE technology appraisal guidance 665
2020	European Network for Health Technology Assessment (EUnetHTA)	Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma. NICE technology appraisal guidance 666
2020	NIHR Health Services and Delivery Research programme	How do different neurodisability services meet the psychosocial support needs of children/young people with feeding disabilities and their families: a national survey and case study approach to mapping and costing service models, care pathways and the child and family experience
2020	European Network for Health Technology Assessment (EUnetHTA)	Cefiderocol for the treatment of infections due to aerobic gram-negative bacteria in adult patients with limited treatment options
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Thoracic and abdominal endovascular repair
2020	National Institute for Health and Care Excellence (NICE)	Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura. NICE technology appraisal guidance 667
2020	NIHR Public Health Research (PHR) programme	A peer-led intervention to promote sexual health in secondary schools: the STASH feasibility study
2020	European Network for Health Technology Assessment (EUnetHTA)	Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy
2020	Malaysian Health Technology Assessment (MaHTAS)	Targeted therapies in combination with hormonal therapy as a first-line treatment for HR+ and HER2- metastatic breast cancer
2020	European Network for Health Technology Assessment (EUnetHTA)	Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB)
2020	Malaysian Health Technology Assessment (MaHTAS)	Refurbished medical device
2020	NIHR Health Technology Assessment programme	Surgical treatments compared with early structured physiotherapy in secondary care for adults with primary frozen shoulder: the UK FROST three-arm RCT
2020	NIHR Health Services and Delivery Research programme	Learning about and learning from GP Federations in the English NHS a qualitative investigation
2020	European Network for Health Technology Assessment (EUnetHTA)	Remdesivir or the treatment of COVID-19. PICO and evidence gaps
2020	Malaysian Health Technology Assessment (MaHTAS)	Resuscitative endovascular balloon occlusion of the aorta (REBOA)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Simulation-based education in surgery: cost-effectiveness and resource use
2020	European Network for Health Technology Assessment (EUnetHTA)	Remdesivir for the treatment of COVID-19
2020	Malaysian Health Technology Assessment (MaHTAS)	Transbronchial cryobiopsy for lung biopsy in interstitial lung disease
2020	European Network for Health Technology Assessment (EUnetHTA)	Dexamethasone for the treatment of hospitalised patients with COVID-19
2020	Malaysian Health Technology Assessment (MaHTAS)	Hepatitis C virus screening and surveillance tests for dialysis patients
2020	National Authority for Assessment and Accreditation in Healthcare (INEAS)	Vaccination contre la grippe dans le contexte particulier de la pandémie COVID-19 : intérêt et populations prioritaires
2020	NIHR Health Technology Assessment programme	A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (FOCUS)
2020	Malaysian Health Technology Assessment (MaHTAS)	Strategies to eliminate mother to child transmission of hepatitis B in Malaysia
2020	NIHR Health Technology Assessment programme	Effectiveness of progesterone to prevent miscarriage in women with early pregnancy bleeding: a randomised placebo-controlled trial (PRISM Trial: PRogesterone In Spontaneous Miscarriage Trial)
2020	Malaysian Health Technology Assessment (MaHTAS)	Pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) for elderly
2020	Scottish Health Technologies Group (SHTG)	HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mogamulizumab (Mycosis Fungoides, Sézary Syndrome)]